Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPN | P05981 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30923148 | 1.00 | HTT (0.68) | HTTKEAP1NFE2L2ALDH1A1MEN1 | |
| SCHEMBL11465754 | 0.82 | KEAP1 (0.50) | HTTKEAP1NFE2L2ALDH1A1MEN1 | |
| SCHEMBL29218271 | 0.82 | KEAP1 (0.50) | HTTKEAP1NFE2L2ALDH1A1MEN1 | |
| SCHEMBL19456984 | 0.81 | HTT (1.00) | HTTALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14412226 | 0.80 | RAB9A (0.59) | HTTALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL19657952 | 0.78 | KEAP1 (0.56) | KEAP1NFE2L2ALDH1A1MEN1MAPT | |
| SCHEMBL28287787 | 0.78 | HPN (0.49) | HTTKEAP1NFE2L2ALDH1A1MEN1 | |
| SCHEMBL16062208 | 0.78 | TP53 (0.49) | KEAP1NFE2L2ALDH1A1MEN1MAPT | |
| SCHEMBL21876434 | 0.78 | KEAP1 (0.67) | KEAP1NFE2L2ALDH1A1MEN1MAPT | |
| SCHEMBL16055914 | 0.76 | HTT (0.59) | HTTKEAP1NFE2L2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110637011-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3596053-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023009475-A1 | ROCK2 INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20210300875-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10961198-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10927082-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200290973-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| US-20200131134-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-30 | — | — | US | disclosed |
| CN-110637011-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2019-12-31 | — | — | CN | disclosed |
| WO-2018170166-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300875-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | HTT 4474/4885KEAP1 621/4885NFE2L2 2167/4885 |
| US-20200131134-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | HTT 4474/4885KEAP1 621/4885NFE2L2 2167/4885 |
| US-20200290973-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | HTT 4474/4885KEAP1 621/4885NFE2L2 2167/4885 |
| US-10961198-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | HTT 4474/4885KEAP1 621/4885NFE2L2 2167/4885 |
| US-10927082-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | HTT 4474/4885KEAP1 621/4885NFE2L2 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.